B

Bioton SA
WSE:BIO

Watchlist Manager
Bioton SA
WSE:BIO
Watchlist
Price: 2.81 PLN -3.77% Market Closed
Market Cap: 241.3m PLN
Have any thoughts about
Bioton SA?
Write Note

Bioton SA
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bioton SA
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
B
Bioton SA
WSE:BIO
Current Portion of Long-Term Debt
zł43.3m
CAGR 3-Years
-9%
CAGR 5-Years
-11%
CAGR 10-Years
-9%
M
Mabion SA
WSE:MAB
Current Portion of Long-Term Debt
zł1.7m
CAGR 3-Years
-54%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
R
Read Gene SA
WSE:RDG
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genomed SA
WSE:GEN
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
U
Urteste SA
WSE:URT
Current Portion of Long-Term Debt
zł315k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Synthaverse SA
WSE:SVE
Current Portion of Long-Term Debt
zł21.2m
CAGR 3-Years
53%
CAGR 5-Years
19%
CAGR 10-Years
N/A
No Stocks Found

Bioton SA
Glance View

Market Cap
241.3m PLN
Industry
Biotechnology

BIOTON SA engages in the manufacture and production of medicine and pharmaceutical substances. The company is headquartered in Warsaw, Woj. Mazowieckie and currently employs 371 full-time employees. The company went IPO on 2005-03-16. The firm is engaged in research, development and wholesale trade of pharmaceutical and biotechnological products. The firm's portfolio consists of oral hypoglycemic drugs (metformin and glimepride) as well as recombinant human insulin in pharmaceutical substance form and for injections. Additionally, the Company provides advertising services. As of December 31, 2011, the Company formed a capital group and operated through its subsidiaries, including BIOTON TRADE Sp. z o.o., Mindar Holdings Ltd, Germonta Holdings Ltd, Tricel SA, SciGen Ltd and BioPartners Holdings AG, among others. On June 12, 2014, it sold a 50% stake in Copernicus Sp. z o.o.

BIO Intrinsic Value
2.83 PLN
Undervaluation 1%
Intrinsic Value
Price
B

See Also

What is Bioton SA's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
43.3m PLN

Based on the financial report for Sep 30, 2024, Bioton SA's Current Portion of Long-Term Debt amounts to 43.3m PLN.

What is Bioton SA's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
-9%

Over the last year, the Current Portion of Long-Term Debt growth was -28%. The average annual Current Portion of Long-Term Debt growth rates for Bioton SA have been -9% over the past three years , -11% over the past five years , and -9% over the past ten years .

Back to Top